COMMUNIQUÉS West-GlobeNewswire

Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study

12/08/2024 - 22:10

Case Series represents second study showing VitaGraft Kidney as a measure of response to the benefit of therapy for one leading cause of allograft failure IRVINE, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp [...]

Surrozen Provides Second Quarter 2024 Financial Results and Business Update

12/08/2024 - 22:05

Enrollment ongoing in SZN-043 Phase 1b trial in patients with Severe Alcoholic Hepatitis Presented first-in-human data from SZN-043 Phase 1a trial at EASL Published study that demonstrated application of unique Targeted [...]

Spectral AI Announces 2024 Second Quarter Financial Results

12/08/2024 - 22:05

Second Quarter Revenue Totals $7.5 Million Total Enrollment Exceeds 85% for Burn Center Pivotal U.S. Clinical Trial Q2 2024 Overview Research & Development Revenue of $7.5 Million Cash Position of $6.9 Million On [...]

Helius Medical Technologies, Inc. Reports Second Quarter 2024 Financial Results

12/08/2024 - 22:05

Company to host call at 4:30pm today NEWTOWN, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel [...]

Stereotaxis Reports 2024 Second Quarter Financial Results

12/08/2024 - 22:05

ST. LOUIS, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second [...]

TELA Bio Reports Second Quarter 2024 Financial Results and Reiterates Full Year 2024 Revenue Guidance

12/08/2024 - 22:05

MALVERN, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions today reported financial [...]

AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

12/08/2024 - 22:05

– Progressing plans to develop ABP-450 (prabotulinumtoxinA) injection as a biosimilar utilizing BOTOX ® (onabotulinumtoxinA) as the reference product – – Scheduled to hold a biosimilar initial advisory meeting with FDA [...]

Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update

12/08/2024 - 22:05

Following FDA consultation, announced plans for validation of the Gen-2 Optejet ® device and 2025 regulatory submission with Mydcombi™ as lead product Advanced Phase 3 CHAPERONE study of MicroPine as a treatment of [...]

Biora Therapeutics Announces Funding Agreement with Existing Investors

12/08/2024 - 22:05

$16 million multiple-draw facility to be used as a bridge to anticipated pharma partnership SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining [...]

ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates

12/08/2024 - 22:05

Initiated dosing of ORIC-944 in combinations with NUBEQA ® (darolutamide) and ERLEADA ® (apalutamide) in the ongoing Phase 1b trial for prostate cancer Entered into clinical trial collaboration and supply agreements [...]

Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12/08/2024 - 22:05

SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on August 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified [...]

Valitor to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

12/08/2024 - 22:05

BERKELEY, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering better medicines to conquer drug limitations, today announced that president and chief scientific officer Wesley Jackson, [...]

Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note

12/08/2024 - 22:05

BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the [...]

Lisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

12/08/2024 - 22:05

Phase 2b ASCEND trial top-line data remains on track to be reported in fourth quarter of 2024 Available cash projected to fund current operations into early 2026 and all active studies through to data Conference call [...]

Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update

12/08/2024 - 22:05

- Phase 2b ODYSSEY Trial in Wet AMD Remains on Track with Topline Data Expected in Late Q3 2024 - - ODYSSEY Safety Review Committee Recommends Trial Continue as Planned with no Serious Adverse Events Observed - - Recent [...]

Adverum Biotechnologies Reports Second Quarter 2024 Financial Results and Provides Program and Corporate Highlights

12/08/2024 - 22:05

- 6E10 dose of Ixo-vec selected for Phase 3 pivotal trials - LUNA 26-week interim analysis presented at ASRS 2024 demonstrating a potential best-in-class product profile of Ixo-vec, with similar efficacy and a favorable [...]

Firefly Neuroscience Announces Closing of Merger Agreement and is Scheduled to Begin Trading on Nasdaq Under the Ticker Symbol ‘AIFF’ on August 13, 2024

12/08/2024 - 22:05

In connection with the consummation of the merger, the Company closed $3.5 million private placement offering FAIRFAX, Va. and TORONTO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “ [...]

Stereotaxis Achieves CE Mark in Europe and Submits 510(k) in the US for Next Generation Robotic System GenesisX

12/08/2024 - 22:03

Latest innovation in Robotic Magnetic Navigation technology supports broad accessibility of robotics for minimally-invasive endovascular surgery GenesisX has obtained CE mark in Europe and has been submitted to the FDA [...]

Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

12/08/2024 - 22:01

New Drug Application for DFD-29 to treat rosacea under FDA review; PDUFA goal date of November 4, 2024 Total revenues for the second quarter ended June 30, 2024 were $14.9 million, a 14% increase from the $13.0 million [...]